PE20240802A1 - Anticuerpos multiespecificos con especificidad para il-4r e il-31 - Google Patents
Anticuerpos multiespecificos con especificidad para il-4r e il-31Info
- Publication number
- PE20240802A1 PE20240802A1 PE2023001896A PE2023001896A PE20240802A1 PE 20240802 A1 PE20240802 A1 PE 20240802A1 PE 2023001896 A PE2023001896 A PE 2023001896A PE 2023001896 A PE2023001896 A PE 2023001896A PE 20240802 A1 PE20240802 A1 PE 20240802A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- sequence
- multispecific antibody
- sequences
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un anticuerpo multiespecifico con especificidad para IL-4R e IL-31, que comprende: a) uno o dos dominios de union, que se unen especificamente a IL-4R (IL4R-BD), y b) uno o dos dominios de union, que se unen especificamente a IL-31 (IL31-BD), en el que el anticuerpo multiespecifico comprende una region Fc de inmunoglobulina; cada uno de dichos IL4R-BD comprende: la secuencia de HCDR1 de SEQ ID NO: 1, las secuencias HCDR2 de SEQ ID NO: 2, la secuencia de HCDR3 de SEQ ID NO: 3, la secuencia de LCDR1 de SEQ ID NO: 7, la secuencia de LCDR2 de SEQ ID NO: 8, y las secuencias LCDR3 de SEQ ID NO: 9; y cada uno de dichos IL31-BD comprende: la secuencia de HCDR1 de SEQ ID NO: 12, la secuencia de HCDR2 de SEQ ID NO: 13, las secuencias HCDR3 de SEQ ID NO: 14, la secuencia de LCDR1 de SEQ ID NO: 17 o 18, la secuencia de LCDR2 de SEQ ID NO: 19, y las secuencias LCDR3 de SEQ ID NO: 20. Tambien se refiere a uno o dos acidos nucleicos que codifican dicho anticuerpo multiespecifico, uno o dos vectores que comprenden dichos acidos nucleicos, una celula huesped que comprende dichos acidos vectores, un procedimiento de produccion de dicho anticuerpo multiespecifico, una composicion farmaceutica que comprende dicho anticuerpo multiespecifico, y su uso en el tratamiento de enfermedades alergicas, inflamatorias y autoinmunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216957.9A EP4019547A1 (en) | 2020-12-23 | 2020-12-23 | Multispecific antibodies having specificity for il-4r and il-31 |
| PCT/EP2021/087561 WO2022136669A1 (en) | 2020-12-23 | 2021-12-23 | Multispecific antibodies having specificity for il-4r and il-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240802A1 true PE20240802A1 (es) | 2024-04-18 |
Family
ID=73857084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001896A PE20240802A1 (es) | 2020-12-23 | 2021-12-23 | Anticuerpos multiespecificos con especificidad para il-4r e il-31 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20250282879A1 (es) |
| EP (2) | EP4019547A1 (es) |
| JP (1) | JP2024501811A (es) |
| KR (1) | KR20230125238A (es) |
| CN (3) | CN116848134A (es) |
| AU (1) | AU2021405058A1 (es) |
| CA (1) | CA3205036A1 (es) |
| CL (1) | CL2023001888A1 (es) |
| CO (1) | CO2023009615A2 (es) |
| CR (1) | CR20230309A (es) |
| DO (1) | DOP2023000130A (es) |
| EC (1) | ECSP23053070A (es) |
| IL (1) | IL303174A (es) |
| MX (1) | MX2023007533A (es) |
| PE (1) | PE20240802A1 (es) |
| SA (1) | SA523441343B1 (es) |
| TW (1) | TW202241966A (es) |
| WO (1) | WO2022136669A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3227014A1 (en) | 2021-08-23 | 2023-03-02 | Ashish Bansal | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| EP4551294A1 (en) | 2022-07-08 | 2025-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist |
| IL319667A (en) * | 2022-09-22 | 2025-05-01 | Biosion Inc | Bispecific recombinant antibodies targeting TSLP and IL4R |
| EP4612183A1 (en) | 2022-11-01 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| EP4622669A1 (en) | 2022-11-23 | 2025-10-01 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
| WO2024206341A1 (en) | 2023-03-27 | 2024-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist |
| US12509510B2 (en) | 2024-04-23 | 2025-12-30 | Attovia Therapeutics, Inc. | IL31-binding polypeptides and uses thereof |
| CN118909130B (zh) * | 2024-08-23 | 2025-10-17 | 普健生物（武汉）科技有限公司 | 抗度普利尤单抗的高亲和力兔单克隆抗体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| AU2007290145B2 (en) * | 2006-09-01 | 2012-11-01 | Zymogenetics, Inc. | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
| RS57520B1 (sr) | 2012-09-07 | 2018-10-31 | Regeneron Pharma | Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
-
2020
- 2020-12-23 EP EP20216957.9A patent/EP4019547A1/en not_active Ceased
-
2021
- 2021-12-23 KR KR1020237024442A patent/KR20230125238A/ko active Pending
- 2021-12-23 CR CR20230309A patent/CR20230309A/es unknown
- 2021-12-23 TW TW110148468A patent/TW202241966A/zh unknown
- 2021-12-23 AU AU2021405058A patent/AU2021405058A1/en active Pending
- 2021-12-23 CN CN202180094017.6A patent/CN116848134A/zh active Pending
- 2021-12-23 CA CA3205036A patent/CA3205036A1/en active Pending
- 2021-12-23 US US18/258,858 patent/US20250282879A1/en active Pending
- 2021-12-23 JP JP2023537629A patent/JP2024501811A/ja active Pending
- 2021-12-23 IL IL303174A patent/IL303174A/en unknown
- 2021-12-23 CN CN202180094172.8A patent/CN116940596A/zh active Pending
- 2021-12-23 MX MX2023007533A patent/MX2023007533A/es unknown
- 2021-12-23 WO PCT/EP2021/087561 patent/WO2022136669A1/en not_active Ceased
- 2021-12-23 CN CN202180085945.6A patent/CN116888151A/zh active Pending
- 2021-12-23 PE PE2023001896A patent/PE20240802A1/es unknown
- 2021-12-23 EP EP21847487.2A patent/EP4267613A1/en active Pending
-
2023
- 2023-06-20 SA SA523441343A patent/SA523441343B1/ar unknown
- 2023-06-22 CL CL2023001888A patent/CL2023001888A1/es unknown
- 2023-06-23 DO DO2023000130A patent/DOP2023000130A/es unknown
- 2023-07-14 EC ECSENADI202353070A patent/ECSP23053070A/es unknown
- 2023-07-19 CO CONC2023/0009615A patent/CO2023009615A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250282879A1 (en) | 2025-09-11 |
| AU2021405058A1 (en) | 2023-06-29 |
| MX2023007533A (es) | 2023-09-19 |
| CN116888151A (zh) | 2023-10-13 |
| AU2021405058A9 (en) | 2024-09-26 |
| EP4019547A1 (en) | 2022-06-29 |
| CN116848134A (zh) | 2023-10-03 |
| CN116940596A (zh) | 2023-10-24 |
| KR20230125238A (ko) | 2023-08-29 |
| ECSP23053070A (es) | 2023-08-31 |
| JP2024501811A (ja) | 2024-01-16 |
| SA523441343B1 (ar) | 2024-10-09 |
| EP4267613A1 (en) | 2023-11-01 |
| WO2022136669A1 (en) | 2022-06-30 |
| CL2023001888A1 (es) | 2023-12-15 |
| CO2023009615A2 (es) | 2023-08-28 |
| CA3205036A1 (en) | 2022-06-30 |
| DOP2023000130A (es) | 2023-09-15 |
| CR20230309A (es) | 2023-10-09 |
| TW202241966A (zh) | 2022-11-01 |
| IL303174A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| JP2022177090A5 (es) | ||
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| JP2017525343A5 (es) | ||
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| SI2970447T1 (en) | PROTITELES AGAINST PAN-ELR + CXC KEMOCIN | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| JP2016520595A5 (es) | ||
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas |